Hari Priya Raghvan, R. Yousuf, Nor Fadzliana Abdullah Thalith, Tang Yee Loong, RS Raja Zahratul Azma
{"title":"抗 JMH 的病例报告:高滴度、低效价抗体给免疫血液学检测带来困难","authors":"Hari Priya Raghvan, R. Yousuf, Nor Fadzliana Abdullah Thalith, Tang Yee Loong, RS Raja Zahratul Azma","doi":"10.32677/ijcr.v10i5.4456","DOIUrl":null,"url":null,"abstract":"This report presents a patient with anti-John Milton Hagen (JMH) posing difficulties in the immunohematological test in the Blood Bank Unit of Universiti Kebangsaan Malaysia Medical Center. A 1-year-8-month-old boy was referred to our center to rule out acute leukemia from a private hospital. A crossmatch request was sent to the Blood Bank before the bone marrow biopsy. Our testing revealed his blood grouping as O Rh-D positive. His Direct Antiglobulin Test was positive, and his antibody screening and antibody identification showed weak pan-reactivity. However, reactions were negative with enzyme-treated cells. Red cell elution showed interestingly no reaction in the eluate, suspected to be due to drug-induced autoantibody. Further tests of antibody titration and neutralization test suggest it could be a high-titer low avidity (HTLA) antibody, most likely Anti-JMH. Although HTLA antibodies are clinically insignificant, they can cause confusion and delay in issuance of blood products. There are also cases of clinically significant HTLA antibodies. Determining the type of HTLA antibody may guide the extent of further testing required to utilize resources best and, most importantly, to assure patient safety.","PeriodicalId":13365,"journal":{"name":"Indian Journal of Case Reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Case report of anti JMH: A high-titer, low-avidity antibody posing difficulty in immunohematological tests\",\"authors\":\"Hari Priya Raghvan, R. Yousuf, Nor Fadzliana Abdullah Thalith, Tang Yee Loong, RS Raja Zahratul Azma\",\"doi\":\"10.32677/ijcr.v10i5.4456\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This report presents a patient with anti-John Milton Hagen (JMH) posing difficulties in the immunohematological test in the Blood Bank Unit of Universiti Kebangsaan Malaysia Medical Center. A 1-year-8-month-old boy was referred to our center to rule out acute leukemia from a private hospital. A crossmatch request was sent to the Blood Bank before the bone marrow biopsy. Our testing revealed his blood grouping as O Rh-D positive. His Direct Antiglobulin Test was positive, and his antibody screening and antibody identification showed weak pan-reactivity. However, reactions were negative with enzyme-treated cells. Red cell elution showed interestingly no reaction in the eluate, suspected to be due to drug-induced autoantibody. Further tests of antibody titration and neutralization test suggest it could be a high-titer low avidity (HTLA) antibody, most likely Anti-JMH. Although HTLA antibodies are clinically insignificant, they can cause confusion and delay in issuance of blood products. There are also cases of clinically significant HTLA antibodies. Determining the type of HTLA antibody may guide the extent of further testing required to utilize resources best and, most importantly, to assure patient safety.\",\"PeriodicalId\":13365,\"journal\":{\"name\":\"Indian Journal of Case Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32677/ijcr.v10i5.4456\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32677/ijcr.v10i5.4456","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
本报告介绍了一名抗约翰-米尔顿-哈根(John Milton Hagen,JMH)患者在马来西亚国民大学医疗中心(Universiti Kebangsaan Malaysia Medical Center)血库科进行免疫血液学检测时遇到的困难。一名一岁八个月大的男童从一家私立医院转诊到本中心,以排除急性白血病的可能。在进行骨髓活检之前,我们向血库发出了交叉配血申请。我们的检测显示他的血型为 O 型 Rh-D 阳性。他的直接抗球蛋白试验呈阳性,抗体筛查和抗体鉴定显示弱泛反应性。但是,酶处理细胞的反应为阴性。有趣的是,红细胞洗脱显示洗脱液中没有反应,怀疑是药物引起的自身抗体所致。进一步的抗体滴定和中和试验表明,这可能是一种高滴度低亲和力(HTLA)抗体,最有可能是抗 JMH。虽然 HTLA 抗体在临床上并不明显,但会造成混淆并延误血液制品的发放。也有临床意义显著的 HTLA 抗体病例。确定 HTLA 抗体的类型可指导所需的进一步检测范围,以充分利用资源,最重要的是确保患者安全。
Case report of anti JMH: A high-titer, low-avidity antibody posing difficulty in immunohematological tests
This report presents a patient with anti-John Milton Hagen (JMH) posing difficulties in the immunohematological test in the Blood Bank Unit of Universiti Kebangsaan Malaysia Medical Center. A 1-year-8-month-old boy was referred to our center to rule out acute leukemia from a private hospital. A crossmatch request was sent to the Blood Bank before the bone marrow biopsy. Our testing revealed his blood grouping as O Rh-D positive. His Direct Antiglobulin Test was positive, and his antibody screening and antibody identification showed weak pan-reactivity. However, reactions were negative with enzyme-treated cells. Red cell elution showed interestingly no reaction in the eluate, suspected to be due to drug-induced autoantibody. Further tests of antibody titration and neutralization test suggest it could be a high-titer low avidity (HTLA) antibody, most likely Anti-JMH. Although HTLA antibodies are clinically insignificant, they can cause confusion and delay in issuance of blood products. There are also cases of clinically significant HTLA antibodies. Determining the type of HTLA antibody may guide the extent of further testing required to utilize resources best and, most importantly, to assure patient safety.